Clinical trial
A Randomized Phase II Study of Sacituzumab Govitecan Alone, Ivonescimab Alone, or Sacituzumab Govitecan and Ivonescimab in Participants With Previously-Treated Actionable Genomic Alteration Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
NCT07393555 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase II Study of Sacituzumab Govitecan Alone, Ivonescimab Alone, or Sacituzumab Govitecan and Ivonescimab in Participants With Previously-Treated Actionable Genomic Alteration Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
- Lead sponsor
- SWOG Cancer Research Network
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- September 22, 2026
- Completion date
- November 30, 2029
- Enrollment
- 117 (estimated)
- Sites
- 41
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent lung non-small cell carcinoma, stage iv lung cancer ajcc v8